Journal
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
Volume 21, Issue 2, Pages 301-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2011.12.004
Keywords
Gastrointestinal stromal tumor; KIT; Tyrosine kinase; Surgery
Funding
- NIH [CA102613]
Ask authors/readers for more resources
Despite being the most common sarcoma of the gastrointestinal tract, gastrointestinal stromal tumor (GIST) has been widely recognized as a unique entity for just over a decade. The advent of tyrosine kinase inhibitors has revolutionized the diagnosis and treatment of GIST. Although surgery remains the only chance for cure, multimodal treatment that includes molecular therapy continues to develop. Optimal management of GIST requires careful radiographic, pathologic, medical, and surgical care, emphasizing the need for a multidisciplinary approach. This review highlights recent developments in the management of GIST.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available